{"id":19932,"date":"2026-06-12T00:28:00","date_gmt":"2026-06-11T22:28:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7d59d925bcd089581d4c69c7aab41809"},"modified":"2026-06-12T00:28:00","modified_gmt":"2026-06-11T22:28:00","slug":"correcting-and-replacing-zetagen-therapeutics-presents-phase-2a-results-at-asco-for-investigational-zetamet-zeta-bc-003-in-metastatic-breast-cancer-patients-with-lytic-bone-lesions","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=19932","title":{"rendered":"CORRECTING and REPLACING Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet\u2122 (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions"},"content":{"rendered":"<p>AUSTIN, Texas--(BUSINESS WIRE)--The company is issuing the following corrected version of the release originally distributed on June 9, 2026.\u00a0In that release, we incorrectly stated that the Phase 2 study reported no treatment\u2011emergent adverse events. The correct statement is that the study reported no treatment\u2011related adverse events. No other data from the study are affected by this correction.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260609691665\/en\/2298901\/5\/Zetagen_logo_horizontal.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260609691665\/en\/2298901\/22\/Zetagen_logo_horizontal.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260609691665\/en\/2298901\/5\/Zetagen_logo_horizontal.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260609691665\/en\/2298901\/21\/Zetagen_logo_horizontal.jpg\" \/><\/a><p>\nZetagen regrets the error and is issuing this clarification to ensure accurate communication.<\/p><p>\nThe updated release reads:<\/p><p class=\"bwalignc\">\n<b>ZETAGEN THERAPEUTICS PRESENTS PHASE 2A RESULTS AT ASCO FOR INVESTIGATIONAL ZETAMET\u2122 (ZETA BC 003) IN METASTATIC BREAST CANCER PATIENTS WITH LYTIC BONE LESIONS<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nA single intratumoral injection resulted in <b>no reported skeletal\u2011related events (SREs) or fractures<\/b><\/li>\n<li>\n<b>No treatment\u2011related adverse events<\/b> (AEs) or serious adverse events (SAEs)<\/li>\n<li>\n<b>Cessation of tumor activity<\/b>, along with reduction in pain scores, and opioid consumption<\/li>\n<li>\n<b>Therapeutic effect observed<\/b> in adjacent, non\u2011injected lesions within the treated vertebral body<\/li>\n<\/ul><p>\nZetagen Therapeutics, a clinical\u2011stage biopharmaceutical company developing novel therapies for primary and metastatic breast cancer, today announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet\u2122 (Zeta BC 003) in subjects with metastatic breast cancer (MBC) with lytic bone lesions.<\/p><p>\nIn this open\u2011label study, no skeletal\u2011related events (SREs) or fractures were observed, no treatment\u2011related adverse events (AEs) or serious adverse events (SAEs) were reported, and cessation of tumor activity was noted in treated vertebral bodies. Zeta BC 003 is an investigational product that has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) and has not been approved by the FDA or any regulatory authority.<\/p><p>\n<i>\u201c<b>We are encouraged by the preliminary findings from this Phase 2a study, which provide important clinical observations on the investigational use of ZetaMet\u2122 in patients with metastatic breast cancer involving bone<\/b>,\u201d<\/i> said Joe C. Loy, President &amp; CEO of Zetagen Therapeutics. <i>\u201c<b>These results also highlight a major achievement for our team, overcoming longstanding industry challenges in intratumoral administration by developing proprietary carriers which deliver compounds that demonstrate solubility and localized bio\u2011adhesion.<\/b>\u201d<\/i><\/p><p>\nThe preliminary findings were presented by Dr. Bryan Margulies, Chief Scientific Officer, and Joe C. Loy, President &amp; CEO, at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 2, 2026. Abstract: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1200%2FJCO.2026.44.16_suppl.589%3Futm_source%3Dcopilot.com&amp;esheet=54550122&amp;newsitemid=20260609691665&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1200%2FJCO.2026.44.16_suppl.589&amp;index=1&amp;md5=568080f472da17a54cce4d94fc4a5fca\" rel=\"nofollow\" shape=\"rect\"><b>https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.589<\/b><\/a><\/p><p>\n<b>Study Overview\n<br\/><\/b>The open\u2011label Phase 2a study (ZGMBC; NCT05280067), conducted at the University of British Columbia, enrolled 10 subjects with a mean age of 52, representing multiple MBC subtypes:<\/p><ul class=\"bwlistdisc\">\n<li>\nHR+ (n=6)<\/li>\n<li>\nHR+\/HER2+ (n=2)<\/li>\n<li>\nHER2+\/HR\u2013 (n=1)<\/li>\n<li>\nTNBC (n=1)<\/li>\n<\/ul><p>\nFive subjects had breakthrough lytic lesions despite prior bisphosphonate therapy. One subject died due to pleural edema, unrelated to study treatment. Across the 10 subjects, 11 target lesions <i><span class=\"bwuline\">received a single intratumoral injection of Zeta BC 003 under sedation<\/span><\/i>. Four adjacent, non\u2011injected lesions were also evaluated.<\/p><p>\n<b>Study Context\n<br\/><\/b>Historical literature reports SRE rates of approximately 53% (Parke et al., <i>Journal Oncologist,<\/i> 2018) in metastatic breast cancer with bone involvement under conventional therapy, with SREs, particularly fractures, associated with a reduction in overall survival of approximately 4.8 months (Saad et al., <i>Journal of the National Cancer Institute<\/i>, 2004).<\/p><p>\n<b>Observed Study Findings<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nNo SREs or fractures reported<\/li>\n<li>\nCessation of tumor activity within treated vertebral bodies<\/li>\n<li>\nTherapeutic spread observed to adjacent, untreated lesions within the same vertebral body<\/li>\n<li>\nNo treatment\u2011related AEs or SAEs<\/li>\n<li>\nMean bone defect volume decreased 65.4% at Day 84 (\u00b120.5%; p=0.0003)<\/li>\n<li>\nMean bone defect volume decreased 84.1% at Day 180 (\u00b113.1%; p&lt;0.0001)<\/li>\n<li>\nPain scores (NRS) decreased by 4.16 points (p&lt;0.05)<\/li>\n<li>\nOpioid use (MED) decreased 33\u201367% among opioid\u2011treated subjects<\/li>\n<li>\nSpinal stability (SINS) improved 18.5% (p&lt;0.05)<\/li>\n<li>\nQuality of life improved:\n<ul class=\"bwlistcircle\">\n<li>\nPCS increased 24.2%<\/li>\n<li>\nMCS increased 12.1%<\/li>\n<\/ul><\/li>\n<\/ul><p>\nWhile cross\u2011study comparisons have inherent limitations, the absence of AEs and SREs in this Phase 2a study provides supportive information for continued investigation.<\/p><p>\nThese observations are also consistent with two published Expanded Access case reports (seven lesions, 2\u2011year follow\u2011up; <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fzetagen.com%2Fpublications%2Ftreating-bone-metastases-with-local-therapy-in-a-breast-cancer-patient-resulted-in-decreased-pain-and-prevented-fracture%2F&amp;esheet=54550122&amp;newsitemid=20260609691665&amp;lan=en-US&amp;anchor=Palma+et+al.%2C+Pain+Management%2C+2023&amp;index=2&amp;md5=6a1d6ccfb0736aa37c021986b3e1613c\" rel=\"nofollow\" shape=\"rect\"><b>Palma et al., <i>Pain Management<\/i>, 2023<\/b><\/a>), which similarly demonstrated absence of SREs, cessation of tumor activity, neo\u2011trabecular bone formation, and therapeutic spread within treated vertebral bodies.<\/p><p>\n<b>Acknowledgment of Clinical Partners\n<br\/><\/b>Zetagen Therapeutics acknowledges and extends its appreciation to the <b>University of British Columbia, Nor Consult, LLC (NorCo), <\/b>and<b> Medical Medics Incorporated<\/b> for their contributions to the ZetaMet\u2122 clinical study. NorCo provided comprehensive clinical operations support, and Medical Medics delivered centralized imaging services that enabled rigorous data quality and standardized imaging assessments throughout the trial.<\/p><p>\n<b>About ZetaMet\u2122 (Zeta BC 003)\n<br\/><\/b>ZetaMet\u2122 is designed for single intratumoral administration into lytic bone lesions associated with metastatic breast cancer. Preclinical and clinical studies suggest the potential for ZetaMet\u2122 to cease lytic activity, reducing pain, initiating bone healing, and prevent SREs; however, ZetaMet\u2122 has not been approved by the FDA or any regulatory authority.<\/p><p>\n<b>About Zetagen Therapeutics\n<br\/><\/b>Zetagen Therapeutics is a clinical\u2011stage biopharmaceutical company focused on developing novel therapies for primary and metastatic breast cancer. The company\u2019s \u201cZeta\u201d\u2011platform is designed to address historical challenges in intratumoral delivery through our proprietary carriers and NMEs to support compound solubility and localized bio\u2011adhesion, with the goal of minimizing off\u2011target toxicity.<\/p><p>\n<b>Forward\u2011Looking Statements\n<br\/><\/b>This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company\u2019s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management\u2019s current beliefs and assumptions.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contact<\/b><br\/>Zetagen Therapeutics, Inc.\n<br\/>Email: <a  href=\"mailto:InvestorRelations@zetagen.com\" rel=\"nofollow\" shape=\"rect\">InvestorRelations@zetagen.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;The company is issuing the following corrected version of the release originally distributed on June 9, 2026.\u00a0In that release, we incorrectly stated that the Phase 2 study reported no treatment\u2011emergent adverse events. T&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19932","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19932"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19932\/revisions"}],"predecessor-version":[{"id":19933,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19932\/revisions\/19933"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}